All posts tagged
Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche
German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases
More News! Shire wows with late-stage clinical results for its potential blockbuster
Gene Therapy, RNA and Pens at European Hemophilia Congress in Paris
How is Biotech Innovating in Hemophilia? Gene Therapy, Antibodies, RNAi… Let’s Review
Shire sells its RNA platform to a US-based Biotech
Results from 45% of Clinical Trials are kept Secret
Shire’s leading Pancreatic Cancer drug is Back with a Bang
The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week!
Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute
UPDATE: Shire to Finally Control Baxalta in a €30 Billion Deal?
Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015
Labiotech UG, All Rights Reserved -
Send this to friend